7 years ago

NodThera Raises £28 Million in Series A Funding

  • NodThera, a Cambridge, UK-based biotechnology company focused on the discovery and development of next generation NLRP3 inflammasome inhibitors, has closed a £28m ($40m) Series A financing round

  • The round was co-led by healthcare investors Sofinnova Partners and 5AM Ventures, with further participation from Epidarex Capital and F-Prime Capital Partners

  • NodThera is developing small molecule inhibitors of the NLRP3 inflammasome, a multi-protein complex which initiates an innate immune response in the body

  • The company is developing its drug candidate through to proof-of-concept in humans in an inflammatory disease and to bring forward further drug candidates specifically addressing high unmet medical needs such as neurodegenerative diseases and certain cancers.

      • ProblemHealthcare

      "making chronic inflammation-related diseases better manageable"

      Solution

      "developing NLRP3 inflammasome inhibitors as small molecule inhibitors"

      Covered on